Given the increasing understanding of molecular mechanisms of NSCLC in response and resistance to EGFR-TKI, additional radiographic strategies for objective response assessment and determination of progression are needed to better guide therapeutic decisions in EGFR-mutant NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.